Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus IRBESARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus IRBESARTAN.
BENICAR HCT vs IRBESARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Irbesartan is an angiotensin II receptor blocker (ARB) that selectively and competitively inhibits the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, thereby blocking vasoconstriction and aldosterone secretion.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
150 mg orally once daily; may increase to 300 mg once daily if needed.
None Documented
None Documented
Clinical Note
moderateIrbesartan + Benzydamine
"The risk or severity of adverse effects can be increased when Irbesartan is combined with Benzydamine."
Clinical Note
moderateIrbesartan + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Irbesartan."
Clinical Note
moderateIrbesartan + Droxicam
"The risk or severity of adverse effects can be increased when Irbesartan is combined with Droxicam."
Clinical Note
moderateIrbesartan + Loxoprofen
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
The terminal elimination half-life of irbesartan is 11–15 hours, supporting once-daily dosing.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Irbesartan is primarily eliminated via biliary/fecal excretion (approximately 80%) and renal excretion (approximately 20%).
Category C
Category D/X
ARB + Thiazide Diuretic
ARB
"The risk or severity of adverse effects can be increased when Irbesartan is combined with Loxoprofen."